279 related articles for article (PubMed ID: 22090452)
1. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
2. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
5. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
7. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
8. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
[TBL] [Abstract][Full Text] [Related]
9. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
[TBL] [Abstract][Full Text] [Related]
10. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
13. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
14. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic prognostication within medulloblastoma subgroups.
Shih DJ; Northcott PA; Remke M; Korshunov A; Ramaswamy V; Kool M; Luu B; Yao Y; Wang X; Dubuc AM; Garzia L; Peacock J; Mack SC; Wu X; Rolider A; Morrissy AS; Cavalli FM; Jones DT; Zitterbart K; Faria CC; Schüller U; Kren L; Kumabe T; Tominaga T; Shin Ra Y; Garami M; Hauser P; Chan JA; Robinson S; Bognár L; Klekner A; Saad AG; Liau LM; Albrecht S; Fontebasso A; Cinalli G; De Antonellis P; Zollo M; Cooper MK; Thompson RC; Bailey S; Lindsey JC; Di Rocco C; Massimi L; Michiels EM; Scherer SW; Phillips JJ; Gupta N; Fan X; Muraszko KM; Vibhakar R; Eberhart CG; Fouladi M; Lach B; Jung S; Wechsler-Reya RJ; Fèvre-Montange M; Jouvet A; Jabado N; Pollack IF; Weiss WA; Lee JY; Cho BK; Kim SK; Wang KC; Leonard JR; Rubin JB; de Torres C; Lavarino C; Mora J; Cho YJ; Tabori U; Olson JM; Gajjar A; Packer RJ; Rutkowski S; Pomeroy SL; French PJ; Kloosterhof NK; Kros JM; Van Meir EG; Clifford SC; Bourdeaut F; Delattre O; Doz FF; Hawkins CE; Malkin D; Grajkowska WA; Perek-Polnik M; Bouffet E; Rutka JT; Pfister SM; Taylor MD
J Clin Oncol; 2014 Mar; 32(9):886-96. PubMed ID: 24493713
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
17. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of chromosome 17p deletions in human medulloblastomas.
Batra SK; McLendon RE; Koo JS; Castelino-Prabhu S; Fuchs HE; Krischer JP; Friedman HS; Bigner DD; Bigner SH
J Neurooncol; 1995; 24(1):39-45. PubMed ID: 8523074
[TBL] [Abstract][Full Text] [Related]
19. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
20. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]